CD8A and neoplasm: These results indicate that HSV-sr39tk/GCV therapy can increase the number of CD4+ and CD8+ cells in the spleen, but only HSV-sr39tk/GCV therapy combined with mIL-3 gene therapy could lead to development of anti-tumor immunity.